Imatinib mesylate effectively treated 12 adults with symptomatic systemic mast cell disease

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1401, 2003-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib mesylate useful prior to stem cell transplant in ALL

By  

Inpharma, Vol. 1, Iss. 1416, 2003-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Imatinib mesylate promising for CML

By  

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

A validated LC method for imatinib mesylate

By Vivekanand V.V.   Sreenivas Rao D.   Vaidyanathan G.   Sekhar N.M.   Avijit Kelkar S.   Ramachandra Puranik P.  

Journal of Pharmaceutical and Biomedical Analysis, Vol. 33, Iss. 5, 2003-12 ,pp. : 879-889

Elsevier

Access to resources Recommend Favorite

Imatinib Mesylate: A Viewpoint by Ian Judson

By Judson I.  

Drugs, Vol. 63, Iss. 5, 2003-01 ,pp. : 523-524

Adis International

Access to resources Recommend Favorite

Imatinib mesylate: response in hypereosinophilic syndrome

By  

Inpharma, Vol. 1, Iss. 1381, 2003-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite